Hosted on MSN4d
FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen
The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell ...
Medscape3d
FDA Approves Grafapex (Treosulfan) for HSCT Conditioning
After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.
Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update
Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million ...
oncnursingnews2d
FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS
Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...
The American Journal of Managed Care3d
Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS
The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell ...
Cure Today2d
FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS
The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...
Monthly Prescribing Reference3d
Grafapex Approved as Part of Conditioning Regimen for HSCT in AML, MDS Patients
The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...
Targeted Oncology2d
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...
Medexus Pharma Shares Higher on FDA Approval for Grafapex
Shares were up 30% to 5.18 Canadian dollars Wednesday. Medexus will target a commercial launch in the first half of calendar 2025. The company believes product-level revenue in the U.S. has the ...
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
Cancer Therapy Advisor3d
Grafapex Approved as Part of Conditioning Regimen for HSCT in AML, MDS
The FDA has approved Grafapex (treosulfan) for use in combination with fludarabine as a preparative regimen for allogeneic HSCT in patients aged 1 year and older with AML or MDS.